Liraglutide vs Dulaglutide

Liraglutide vs Dulaglutide: Overview

Liraglutide and dulaglutide are both well-established glucagon-like peptide-1 (GLP-1) receptor agonists that have played central roles in the management of type 2 diabetes mellitus and, in the case of liraglutide, chronic weight management. Liraglutide is marketed as Victoza for type 2 diabetes (once-daily injection) and Saxenda for weight management (at a higher dose), while dulaglutide is marketed as Trulicity for type 2 diabetes (once-weekly injection). The liraglutide vs dulaglutide comparison has been directly addressed in the AWARD-6 clinical trial, providing robust head-to-head evidence.

These two agents represent the transition within the GLP-1 receptor agonist class from daily to weekly dosing regimens. Liraglutide, approved in 2010, was among the first long-acting GLP-1 agonists but still requires daily administration. Dulaglutide, approved in 2014, offered the convenience of once-weekly dosing. The Victoza vs Trulicity comparison is thus relevant not only for efficacy and safety but also for understanding the practical implications of dosing frequency on patient adherence and outcomes.

The comparison between these agents also touches on the distinct positioning of liraglutide in weight management. While Saxenda is approved for obesity treatment, dulaglutide (Trulicity) is not, creating a Saxenda vs Trulicity discussion that reflects different approved indications despite both agents producing weight reduction as part of their pharmacological profile.

Mechanism of Action

Both liraglutide and dulaglutide activate the GLP-1 receptor, producing the characteristic incretin effects: enhanced glucose-dependent insulin secretion, suppressed glucagon release, delayed gastric emptying, and central appetite reduction through hypothalamic and brainstem GLP-1 receptor engagement.

Liraglutide is a GLP-1 analogue with 97% amino acid sequence homology to native human GLP-1. It incorporates a single amino acid substitution (Arg34Lys) and is acylated with a C16 fatty acid (palmitic acid) at position 26 via a glutamic acid spacer. This acylation promotes non-covalent albumin binding, which reduces renal clearance and extends the half-life to approximately 13 hours — sufficient for once-daily dosing but not for weekly administration.

Dulaglutide employs a fundamentally different molecular strategy. It consists of two GLP-1 analogue molecules covalently linked to a modified human immunoglobulin G4 (IgG4) Fc fragment via small peptide linkers. This large fusion protein (~63 kDa) achieves a half-life of approximately 5 days through reduced renal filtration (due to its size) and FcRn-mediated recycling. The GLP-1 analogue component includes amino acid modifications that confer DPP-4 resistance while maintaining receptor affinity.

Clinical Evidence

The AWARD-6 trial provides the most direct clinical evidence for the liraglutide vs dulaglutide comparison. This randomised, open-label, phase 3 trial compared once-weekly dulaglutide 1.5 mg with once-daily liraglutide 1.8 mg in adults with type 2 diabetes inadequately controlled on metformin (Dungan et al., 2014). The trial demonstrated that dulaglutide was non-inferior to liraglutide for HbA1c reduction over 26 weeks, with both agents producing clinically meaningful glycaemic improvements.

Both agents have been evaluated in cardiovascular outcomes trials. The LEADER trial (Marso et al., 2016) demonstrated that liraglutide reduced the risk of major adverse cardiovascular events by 13% compared to placebo in patients with type 2 diabetes and high cardiovascular risk — a landmark finding for the GLP-1 receptor agonist class. The REWIND trial (Gerstein et al., 2019) subsequently demonstrated that dulaglutide reduced MACE by 12% compared to placebo, notably in a population that included a majority of patients without established cardiovascular disease.

For weight management, liraglutide at the higher 3.0 mg daily dose (Saxenda) has been evaluated in the SCALE trial programme, demonstrating approximately 8% mean body weight reduction in adults with obesity. Dulaglutide has not been studied at higher doses specifically for weight management, and the weight loss observed with Trulicity at its approved doses for diabetes is generally more modest.

Efficacy Comparison

In the AWARD-6 trial, dulaglutide 1.5 mg once weekly produced a mean HbA1c reduction of 1.42 percentage points compared to 1.36 percentage points with liraglutide 1.8 mg once daily, confirming statistical non-inferiority. Both agents achieved similar proportions of participants reaching HbA1c targets below 7.0%. Dungan et al. (2016) further analysed composite endpoints from the AWARD programme, demonstrating that dulaglutide achieved favourable rates of combined glycaemic, weight, and hypoglycaemia targets.

Weight reduction in AWARD-6 was modestly but statistically significantly greater with liraglutide (3.6 kg) than dulaglutide (2.9 kg), though both agents produced clinically meaningful weight loss. This difference may reflect the more frequent daily dosing of liraglutide producing more consistent appetite suppression, or the specific pharmacological characteristics of each molecule. The Victoza vs Trulicity comparison for weight therefore shows a slight advantage for liraglutide at their respective approved diabetes doses.

When considering the weight management indication specifically, the Saxenda vs Trulicity comparison is more pronounced. Liraglutide 3.0 mg (Saxenda) produces substantially greater weight loss than dulaglutide at its approved diabetes doses, reflecting both the higher dose used and the approved indication for obesity management. However, it should be noted that newer GLP-1 and dual-agonist therapies have since surpassed both agents in weight loss magnitude.

Safety and Tolerability

Both liraglutide and dulaglutide demonstrate the gastrointestinal adverse event profile characteristic of GLP-1 receptor agonists. Nausea is the most frequently reported adverse event with both agents, followed by diarrhoea and vomiting. In the AWARD-6 trial, gastrointestinal adverse events were reported more frequently with liraglutide (36%) than dulaglutide (36% — rates were similar), though nausea specifically was comparable between groups.

The LEADER trial provided extensive long-term safety data for liraglutide over a median follow-up of 3.8 years, confirming an acceptable safety profile with cardiovascular benefit. Similarly, the REWIND trial followed dulaglutide-treated patients for a median of 5.4 years, providing among the longest safety follow-up data for any GLP-1 receptor agonist. Both trials confirmed low rates of serious adverse events including pancreatitis.

Injection site reactions differ somewhat between the agents. Liraglutide is administered via a multi-dose pen requiring daily injection, which may increase the cumulative risk of injection site reactions over time. Dulaglutide’s single-use, auto-injector pen with a hidden needle may improve patient acceptance, particularly in those with needle aversion. Both agents carry class-level thyroid C-cell tumour warnings and contraindications in personal or family history of medullary thyroid carcinoma.

Pharmacokinetics

The pharmacokinetic profiles of liraglutide and dulaglutide reflect their different molecular strategies for half-life extension. Liraglutide achieves a half-life of approximately 13 hours through albumin binding mediated by its C16 fatty acid chain. While this represents a substantial improvement over native GLP-1 (half-life 2-3 minutes), it remains insufficient for less-than-daily dosing. Peak concentrations occur approximately 8-12 hours post-injection, and once-daily administration produces relatively consistent drug levels with modest peak-to-trough variation.

Dulaglutide’s IgG4 Fc fusion strategy produces a half-life of approximately 5 days, enabling once-weekly administration. Steady-state concentrations are achieved after 2-4 weeks of weekly dosing. The large molecular size reduces distribution into tissues but provides prolonged systemic exposure. Peak concentrations occur approximately 24-72 hours after injection.

Both agents are primarily eliminated through general protein catabolism rather than specific organ-mediated clearance, making hepatic or renal dose adjustments unnecessary in mild-to-moderate impairment. The route of administration is subcutaneous for both, though liraglutide uses a daily multi-dose pen while dulaglutide employs a weekly single-dose auto-injector. This dosing frequency difference represents perhaps the most practically significant pharmacokinetic distinction between the two agents.

Current Research Status

Liraglutide is FDA-approved for type 2 diabetes (Victoza, once-daily 1.2/1.8 mg) and chronic weight management (Saxenda, once-daily 3.0 mg), with a cardiovascular risk reduction indication based on LEADER data. While liraglutide remains available and prescribed, its market position has been significantly affected by the introduction of once-weekly agents offering superior convenience and, in several cases, greater efficacy. Research interest has diminished relative to newer-generation GLP-1 agonists.

Dulaglutide (Trulicity) holds FDA approval for type 2 diabetes with a cardiovascular risk reduction indication based on REWIND data. It remains one of the most widely prescribed GLP-1 receptor agonists globally, particularly in markets where cost and accessibility are primary considerations. Ongoing research includes real-world effectiveness studies and cost-effectiveness analyses across healthcare systems, such as the analysis by Dilla et al. (2017) comparing the cost-effectiveness of dulaglutide versus liraglutide.

Both agents are positioned as established, well-characterised GLP-1 receptor agonists within a class that continues to expand. Network meta-analyses and scoping reviews, such as the assessment by Nunns et al. (2025), continue to contextualise their relative effectiveness within the broader landscape of incretin-based therapies.

Summary

Liraglutide and dulaglutide are well-established GLP-1 receptor agonists with comparable glycaemic efficacy, as demonstrated by the AWARD-6 non-inferiority trial. Key differences include dosing frequency (daily vs weekly), molecular design (acylated peptide vs Fc fusion protein), and approved indications (liraglutide has an obesity indication as Saxenda; dulaglutide does not). Both agents have demonstrated cardiovascular benefit in dedicated outcomes trials (LEADER and REWIND, respectively). Liraglutide may produce slightly greater weight reduction at approved diabetes doses, but dulaglutide’s once-weekly convenience represents a significant practical advantage. Both agents have been somewhat surpassed in efficacy by newer-generation therapies including semaglutide and tirzepatide, but they remain relevant options, particularly the Victoza vs Trulicity choice in settings where cost, availability, and extensive long-term safety data inform prescribing decisions.

References

• Dungan KM et al. (2014). Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet. PMID: 25018121
• Dungan KM et al. (2016). Achieving the composite endpoint of glycated haemoglobin less than 7.0%, no weight gain and no hypoglycaemia in the once-weekly dulaglutide AWARD programme. Diabetes, Obesity and Metabolism. PMID: 26362460
• Marso SP et al. (2016). Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. PMID: 27295427
• Gerstein HC et al. (2019). Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. PMID: 31189511
• Dilla T et al. (2017). The cost-effectiveness of dulaglutide versus liraglutide for the treatment of type 2 diabetes mellitus in Spain in patients with BMI ≥30 kg/m². Journal of Medical Economics. PMID: 28008768
• Nunns M et al. (2025). The quantity, quality and findings of network meta-analyses evaluating the effectiveness of GLP-1 RAs for weight loss: a scoping review. Health Technology Assessment. PMID: 40580049
• Raza SS et al. (2025). Medical Management of Obesity: A Comprehensive Review of FDA-Approved and Investigational Therapies. Cureus. PMID: 41393574